Literature DB >> 12534589

Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds.

L Chambers1, S Woodrow, A P Brown, P D Harris, D Phillips, M Hall, J C T Church, D I Pritchard.   

Abstract

BACKGROUND: Larvae of the greenbottle fly Lucilia sericata are used routinely for the clinical treatment of difficult necrotic and infected wounds. Degradation by proteinases contained in larval excretory/secretory (ES) products is thought to contribute to wound debridement by removal of dead tissue. However, proteinase activity may also affect host tissue remodelling processes.
OBJECTIVES: To identify proteolytic enzymes derived from L. sericata ES products with activities against fibrin and extracellular matrix (ECM) components.
METHODS: Larval proteinase activities were assayed in vitro using class-specific substrates and inhibitors. Their action against fibrin and ECM components was examined using sodium dodecyl sulphate-polyacrylamide gel electrophoresis.
RESULTS: Three classes of proteolytic enzyme were detected in the secretions using fluorescein isothiocyanate-labelled casein as a model substrate. The predominant activity belonged to serine proteinases (pH optima 8-9) of two different subclasses (trypsin-like and chymotrypsin-like), with a weaker aspartyl proteinase (pH 5) and a metalloproteinase (pH 9) with exopeptidase characteristics also present. Using skin-relevant ECM components as substrates L. sericata ES products solubilized fibrin clots and degraded fibronectin, laminin and acid-solubilized collagen types I and III. Hydrolysis of ECM macromolecules was inhibited by preincubating ES products with phenylmethylsulphonyl fluoride but not 4-amidinophenylmethylsulphonyl fluoride, indicating that degradation was due to the 'chymotrypsin-like' serine proteinase.
CONCLUSIONS: These data suggest that a combination of L. sericata ES proteinases involving chymotrypsin-like and trypsin-like activities could potentially influence wound healing events when maggots are introduced into necrotic and infected wounds, with the chymotrypsin-like activity involved in the remodelling of ECM components.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534589     DOI: 10.1046/j.1365-2133.2003.04935.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  42 in total

1.  Maggot debridement therapy in the treatment of complex diabetic wounds.

Authors:  Michelle L Marineau; Mark T Herrington; Karen M Swenor; Lawrence J Eron
Journal:  Hawaii Med J       Date:  2011-06

2.  [Wound debridement and treatment of ulcus cruris. Conservative and operative therapeutic procedures].

Authors:  H Stege; R Mang
Journal:  Hautarzt       Date:  2003-11       Impact factor: 0.751

Review 3.  Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential.

Authors:  Iain S Whitaker; Christopher Twine; Michael J Whitaker; Mathew Welck; Charles S Brown; Ahmed Shandall
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

4.  The cost of wound debridement: a Canadian perspective.

Authors:  Kevin Y Woo; David Keast; Nancy Parsons; R Gary Sibbald; Nicole Mittmann
Journal:  Int Wound J       Date:  2013-07-09       Impact factor: 3.315

Review 5.  TIME management by medicinal larvae.

Authors:  David I Pritchard; Václav Čeřovský; Yamni Nigam; Samantha F Pickles; Gwendolyn Cazander; Peter H Nibbering; Anke Bültemann; Wilhelm Jung
Journal:  Int Wound J       Date:  2015-07-15       Impact factor: 3.315

6.  Histological patterns in healing chronic wounds using Cochliomyia macellaria (Diptera: Calliphoridae) larvae and other therapeutic measures.

Authors:  Franciéle Souza de Masiero; Mariana Prado Nassu; Mauro Pereira Soares; Patricia Jacqueline Thyssen
Journal:  Parasitol Res       Date:  2015-04-24       Impact factor: 2.289

7.  First Record of Larval Secretions of Cochliomyia macellaria (Fabricius, 1775) (Diptera: Calliphoridae) Inhibiting the Growth of Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  F S Masiero; M F K Aquino; M P Nassu; D I B Pereira; D S Leite; P J Thyssen
Journal:  Neotrop Entomol       Date:  2016-10-01       Impact factor: 1.434

8.  Fatty acid extracts from Lucilia sericata larvae promote murine cutaneous wound healing by angiogenic activity.

Authors:  Zhen Zhang; Shouyu Wang; Yunpeng Diao; Jianing Zhang; Decheng Lv
Journal:  Lipids Health Dis       Date:  2010-03-08       Impact factor: 3.876

9.  A novel approach to the antimicrobial activity of maggot debridement therapy.

Authors:  Anders S Andersen; Dorthe Sandvang; Kirk M Schnorr; Thomas Kruse; Søren Neve; Bo Joergensen; Tonny Karlsmark; Karen A Krogfelt
Journal:  J Antimicrob Chemother       Date:  2010-06-11       Impact factor: 5.790

10.  Larval therapy for leg ulcers (VenUS II): randomised controlled trial.

Authors:  Jo C Dumville; Gill Worthy; J Martin Bland; Nicky Cullum; Christopher Dowson; Cynthia Iglesias; Joanne L Mitchell; E Andrea Nelson; Marta O Soares; David J Torgerson
Journal:  BMJ       Date:  2009-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.